Home › Funds › Consolidated Portfolio Review Corp › ROIV

Consolidated Portfolio Review Corp position in ROIV

ROIVANT SCIENCES LTD · Health Care

Consolidated Portfolio Review Corp reported holding 276,530 shares of ROIV (ROIVANT SCIENCES LTD) in its Q3 2026 13F filing — a position valued at US$10.1M, representing 0.82% of its reported portfolio and ranking #18 among its reported holdings. Consolidated Portfolio Review Corp has disclosed ROIV holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

Latest position (Q3 2026)276.53K sh
Reported value held$10.11M
Portfolio Weight0.82%
First reportedQ4 2025
Last changeHold
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Consolidated Portfolio Review Corp's ROIV position evolved

Consolidated Portfolio Review Corp first disclosed a stake in ROIV in Q4 2025 at 276,530 shares (US$6.0M). The position peaked in Q3 2026 at 276,530 shares, worth US$10.1M. Across 4 filings, Consolidated Portfolio Review Corp held the position steady without any share-count change. The most recent filing (Q3 2026) shows 276,530 shares valued at US$10.1M.

Quarter by quarter

QuarterSharesValueChange
Q4 2025 276.53K $6.00M New
Q1 2026 276.53K $7.66M Hold
Q2 2026 276.53K $9.79M Hold
Q3 2026 276.53K $10.11M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ROIV and 13F data

ROIV (ROIVANT SCIENCES LTD) is a Health Care company. 62 other funds we track also report a position in ROIV — the largest reported positions include QVT Financial LP (US$839.6M), Farallon Capital Management (US$506.4M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$506.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ROIV

All ROIV fund holders →

FAQ

How long has Consolidated Portfolio Review Corp held ROIV?

Consolidated Portfolio Review Corp has disclosed ROIV holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

What is Consolidated Portfolio Review Corp's current position in ROIV?

As of Q3 2026, Consolidated Portfolio Review Corp holds 276.53K shares of ROIV (ROIVANT SCIENCES LTD), valued at $10.11M, representing 0.82% of its reported portfolio and ranking #18.

Has Consolidated Portfolio Review Corp been buying or selling ROIV?

In the latest 13F filing (Q3 2026), Consolidated Portfolio Review Corp held unchanged its position in ROIV. The position peaked in Q3 2026 at 276.53K shares.

Which other funds hold ROIV?

Other major institutional holders of ROIV include QVT Financial LP, Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., among 62 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.